Should You Buy Moderna Stock? Why Many Wall Street Analysts Say "No."
Following last month's super rally, a growing number of analysts are now calling for caution.
Overview
Moderna (NASDAQ: MRNA) has remained one of the market's hottest biotech stocks. Even as the vaccine maker's shares remain off their 52-week high, hit by news of a breakthrough in using its mRNA technology to create marketable drugs for other diseases and ailments, not just for COVID-19, at around $157 per share, they're still up over sixfold over the past 12 months.
Yet while Moderna may still be sitting pretty right now, analysts remain skeptical whether the stock can hold on to its latest spate of gains.
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.